# MyCellHub

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mycellhub

- Industry: Healthcare IT
- Headquarters: Hasselt, Belgium
- Website: www.mycellhub.com
- Total disclosed funding: $1.2M
- Latest round: Seed (Sep 6, 2019)
- Investors on record: 4

## About

MyCellHub BV is a Belgian company specializing in Bio-Manufacturing Execution Systems designed for Good Manufacturing Practice environments, enhancing efficiency in advanced therapy production through streamlined processes and regulatory compliance.Founded by Sébastien de Bournonville, Thomas Pinna, and Toon Lambrechts, MyCellHub BV focuses on digitalizing biomanufacturing processes. The company is headquartered in Belgium and has received EUR 1.1 million in Seed funding from K.U. Leuven Research & Development, Noshaq, The Co-Foundry, and The Faktory as of September 12, 2019. CEO Jacques Parlongue leads the company, which has not reported any significant pivots or changes in operations since its inception.MyCellHub specializes in providing a comprehensive Bio-Manufacturing Execution System (BES) tailored for Good Manufacturing Practice (GMP) environments. The core product focuses on digitalizing advanced therapy production processes, allowing facilities to enhance manufacturing efficiency through streamlined data collection, review, and approval workflows. With features such as electronic batch records, interactive work instructions, and compliance with 21 CFR part 11 and EU Vol 4 annex 11, the system is designed to optimize operations while ensuring regulatory adherence. Targeted primarily at cell and gene therapy developers and Contract Development and Manufacturing Organizations (CDMOs), MyCellHub’s software enhances collaboration among various departments by eliminating fragmented paperwork and facilitating real-time access to critical production data. The primary geographical markets include Europe and North America, where the demand for GMP-compliant manufacturing solutions is increasingly prominent.MyCellHub operates on a subscription-based revenue model, providing clients with access to its software for bio-manufacturing processes. Transactions typically involve service agreements where clients pay fees for access to the software platform, which includes a suite of modules encompassing batch records, environmental monitoring, and equipment management. These service plans are structured to facilitate ongoing support and updates, ensuring compliance and operational efficiency. The company caters primarily to B2B clients within the biopharmaceutical sector, focusing on long-term partnerships with organizations engaged in advanced therapies. Specific pricing plans are designed around the needs of each client, offering scalability based on the size and complexity of the operations being managed. The EBITDA for the most recent year, 2024, stands at EUR -427,616.80.

## Funding rounds

- Seed, Sep 6, 2019, $1.2M — K.U. Leuven Research & Development, Noshaq, The Co-Foundry, The Faktory

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Seed
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Seed
- The Co-Foundry — Seed
- The Faktory (https://capitalatlas.ai/funds/the-faktory) — Seed